A new radioimmunotherapy approach has been shown to successfully eliminate cancer stem cells (CSCs) in preclinical models of ...

A new radioimmunotherapy approach has been shown to successfully eliminate cancer stem cells (CSCs) in preclinical models ...

Radioimmunotherapy represents an emerging approach for the treatment of HGG. Radioimmunotherapy utilizes a molecular vehicle (monoclonal antibodies) to deliver a radionuclide (the drug) to a ...

ORLANDO, Fla., Dec. 6, 2010 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the ...

In a 2022 interview at the World Conference on Lung Cancer, Gerard M. Walls, MB, MRCP, MSc, of Queen's University Belfast in Northern Ireland, summed up the aims of radioimmunotherapy, explaining that ...

One such radioimmunotherapy, 90Y-clivatuzumab tetraxetan, was used in this trial: PAM4 is the antibody and yttrium-90 (90Y) is the source of radiotherapy, and they are held together by a linker.

Radioimmunotherapy: Promising Treatment For HIV Infection And Viral Cancers Date: February 23, 2009 Source: Albert Einstein College of Medicine Summary: Scientists have piggybacked antibodies onto ...

A major advance in cancer therapy—high dose radioimmunotherapy—resulted in long-term remission for persons with mantle cell lymphoma. This often-fatal form of Non-Hodgkin’s Lymphoma (NHL ...

Radioimmunotherapy Treatment Market: Regional Overview Region wise, the global Radioimmunotherapy Treatment Market is classified into regions namely, North America, Latin America, Western Europe, ...

New pretargeted radioimmunotherapy for colorectal cancer Date: June 6, 2011 Source: Society of Nuclear Medicine Summary: Results from a Phase 1 clinical trial for a cancer therapy show the ...

A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of ...

A literature analysis showed that the published studies concerning 'radioimmunotherapy' and 'gliomas' in the last 5 years (2008–2012) are less than half of those published on the same topic ...